- Home
- PYPD vs KG Comparison
PYPD vs KG Comparison
Compare PYPD & KG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PYPD | KG |
|---|---|---|
| Founded | 2008 | N/A |
| Country | Israel | Bermuda |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.0M | 87.3M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PYPD | KG |
|---|---|---|
| Price | $5.69 | $4.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $11.40 | N/A |
| AVG Volume (30 Days) | ★ 112.1K | 14.2K |
| Earning Date | 11-11-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1819.15 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $34,049,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 785.08 |
| 52 Week Low | $3.50 | $4.00 |
| 52 Week High | $5.84 | $23.89 |
Technical Indicators
Market Signals| Indicator | PYPD | KG |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 33.45 |
| Support Level | $4.18 | N/A |
| Resistance Level | $5.58 | $5.54 |
| Average True Range (ATR) | 0.26 | 0.45 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 78.86 | 5.69 |
Price Performance
Historical ComparisonAbout PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. The company's product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About KG Kestrel Group Ltd.
Kestrel Group Ltd specializes in providing fronting services to insurance program managers, MGAs, reinsurers, and reinsurance brokers with two reportable segments: Program Services and Legacy Reinsurance. The Group facilitates insurance transactions utilizing its management contracts with four insurance carriers. Its line business includes casualty, workers' compensation, catastrophe-exposed property, and non-catastrophe-exposed property, with diverse risk durations, sizes, and product types.